Yutaka Kawakami

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9496657/publications.pdf

Version: 2024-02-01

237	17,704	17405	16127
papers	citations	63 h-index	124 g-index

242	242	242	21195
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine, 1998, 4, 321-327.	15.2	1,693
2	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet, The, 2018, 391, 2128-2139.	6.3	1,487
3	Towards the introduction of the â€˜Immunoscoreâ€™ in the classification of malignant tumours. Journal of Pathology, 2014, 232, 199-209.	2.1	1,151
4	Cancer Metastasis Is Accelerated through Immunosuppression during Snail-Induced EMT of Cancer Cells. Cancer Cell, 2009, 15, 195-206.	7.7	735
5	Cancer classification using the Immunoscore: a worldwide task force. Journal of Translational Medicine, 2012, 10, 205.	1.8	676
6	The BRAFâ€“MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. Journal of Experimental Medicine, 2006, 203, 1651-1656.	4.2	614
7	RNA helicase encoded by melanoma differentiationâ€“associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis and Rheumatism, 2009, 60, 2193-2200.	6.7	511
8	Identification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes. Journal of Experimental Medicine, 1996, 184, 2207-2216.	4.2	287
9	Human circulating CD14+monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. Journal of Leukocyte Biology, 2003, 74, 833-845.	1.5	275
10	Defective vasculogenesis in systemic sclerosis. Lancet, The, 2004, 364, 603-610.	6.3	261
11	Molecular Characterization of Defective Antigen Processing in Human Prostate Cancer. Journal of the National Cancer Institute, 1995, 87, 280-285.	3.0	205
12	Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene, 2004, 23, 6031-6039.	2.6	177
13	Optimization of an siRNA-expression system with an improved hairpin and its significant suppressive effects in mammalian cells. Journal of Gene Medicine, 2004, 6, 715-723.	1.4	161
14	Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase. Journal of Investigative Dermatology, 2016, 136, 255-263.	0.3	160
15	Expression of the neural RNA-binding protein Musashi1 in human gliomas. Glia, 2001, 34, 1-7.	2.5	155
16	Spleen Is a Primary Site for Activation of Platelet-Reactive T and B Cells in Patients with Immune Thrombocytopenic Purpura. Journal of Immunology, 2002, 168, 3675-3682.	0.4	139
17	Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine, 2011, 9, 214.	1.8	139
18	Immune Suppression and Resistance Mediated by Constitutive Activation of Wnt/Î²-Catenin Signaling in Human Melanoma Cells. Journal of Immunology, 2012, 189, 2110-2117.	0.4	136

#	Article	IF	Citations
19	Induction of antigen-specific human CD4+ T cell anergy by peripheral blood DC2 precursors. European Journal of Immunology, 2001, 31, 2547-2557.	1.6	134
20	Pivotal Roles of T-Helper 17-Related Cytokines, IL-17, IL-22, and IL-23, in Inflammatory Diseases. Clinical and Developmental Immunology, 2013, 2013, 1-13.	3.3	132
21	Analysis of Expression of the Melanoma-Associated Antigens MART-1 and gp lOO in Metastatic Melanoma Cell Lines and in In Situ Lesions. Journal of Immunotherapy, 1996, 19, 192-205.	1.2	130
22	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. Journal of Clinical Oncology, 2020, 38, 3638-3651.	0.8	130
23	Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis and Rheumatism, 2000, 43, 1074.	6.7	125
24	Recognition of Shared Melanoma Antigens in Association With Major HLA-A Alleles by Tumor Infiltrating T Lymphocytes From 123 Patients With Melanoma. Journal of Immunotherapy, 2000, 23, 17-27.	1.2	125
25	CCL2 is critical for immunosuppression to promote cancer metastasis. Clinical and Experimental Metastasis, 2013, 30, 393-405.	1.7	120
26	Human tumor antigens recognized by T-cells. Immunologic Research, 1997, 16, 313-339.	1.3	119
27	Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura. Blood, 2001, 98, 130-139.	0.6	117
28	Endothelial Differentiation Potential of Human Monocyte-Derived Multipotential Cells. Stem Cells, 2006, 24, 2733-2743.	1.4	116
29	Molecular Mechanisms Used by Tumors to Escape Immune Recognition. Journal of Immunotherapy, 1993, 14, 182-190.	1.2	115
30	Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. International Journal of Cancer, 1995, 62, 97-102.	2.3	115
31	Helicobacter pylori eradication shifts monocyte Fcî³ receptor balance toward inhibitory Fcî³RIIB in immune thrombocytopenic purpura patients. Journal of Clinical Investigation, 2008, 118, 2939-49.	3.9	114
32	Periductal Area as the Primary Site for T-Cell Activation in Lacrimal Gland Chronic Graft-Versus-Host Disease. , 2003, 44, 1888.		111
33	Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clinical Cancer Research, 2011, 17, 3064-3076.	3.2	108
34	The mechanisms of cancer immunoescape and development of overcoming strategies. International Journal of Hematology, 2011, 93, 294-300.	0.7	106
35	Generation of Human Melanocytes from Induced Pluripotent Stem Cells. PLoS ONE, 2011, 6, e16182.	1.1	102
36	Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. Journal of Immunological Methods, 1997, 202, 13-25.	0.6	97

#	Article	IF	Citations
37	A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology, 2003, 37, 1267-1276.	3.6	95
38	Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. Cancer Research, 2003, 63, 5564-72.	0.4	94
39	Binding of Î²2â€“glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood, 2005, 105, 1552-1557.	0.6	92
40	The Use of Melanosomal Proteins in the Immunotherapy of Melanoma. Journal of Immunotherapy, 1998, 21, 237-246.	1.2	91
41	Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines. Oncogene, 2004, 23, 8796-8804.	2.6	91
42	Enhancement of Immunologic Tumor Regression by Intratumoral Administration of Dendritic Cells in Combination with Cryoablative Tumor Pretreatment and Bacillus Calmette-Guerin Cell Wall Skeleton Stimulation. Clinical Cancer Research, 2006, 12, 7465-7475.	3.2	91
43	Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis and Rheumatism, 2006, 54, 1946-1951.	6.7	90
44	Immunobiology of Human Melanoma Antigens MART-1 and gp100 and their Use for Immuno-Gene Therapy. International Reviews of Immunology, 1997, 14, 173-192.	1.5	87
45	Enhanced Cancer Immunotherapy Using STAT3-Depleted Dendritic Cells with High Th1-Inducing Ability and Resistance to Cancer Cell-Derived Inhibitory Factors. Journal of Immunology, 2011, 187, 27-36.	0.4	87
46	Marijuana components suppress induction and cytolytic function of murine cytotoxic T cells in vitro and in vivo. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1991, 32, 465-477.	1.1	85
47	Intratumoural-infiltrating CD4â€‰+â€‰and FOXP3â€‰+â€‰T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer. British Journal of Cancer, 2019, 121, 659-665.	2.9	84
48	Macrophage migration inhibitory factor (MIF) promotes cell survival and proliferation of neural stem/progenitor cells. Journal of Cell Science, 2012, 125, 3210-20.	1.2	82
49	Downregulation of KIF23 suppresses glioma proliferation. Journal of Neuro-Oncology, 2012, 106, 519-529.	1.4	82
50	Novel autoantibodies to a voltage-gated potassium channel KV1.4 in a severe form of myasthenia gravis. Journal of Neuroimmunology, 2005, 170, 141-149.	1.1	75
51	A phase Î™I study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). Journal of Translational Medicine, 2014, 12, 108.	1.8	75
52	Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. British Journal of Haematology, 2001, 112, 916-926.	1.2	74
53	Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: Relationship to thrombocytopenia with megakaryocytic hypoplasia. Arthritis and Rheumatism, 2002, 46, 2148-2159.	6.7	74
54	Implantation of dendritic cells in injured adult spinal cord results in activation of endogenous neural stem/progenitor cells leading to de novo neurogenesis and functional recovery. Journal of Neuroscience Research, 2004, 76, 453-465.	1.3	72

#	Article	IF	Citations
55	Targeting FSTL1 Prevents Tumor Bone Metastasis and Consequent Immune Dysfunction. Cancer Research, 2013, 73, 6185-6193.	0.4	72
56	Autoreactive CD4+ T-cell clones to Î²2-glycoprotein I in patients with antiphospholipid syndrome: preferential recognition of the major phospholipid-binding site. Blood, 2001, 98, 1889-1896.	0.6	71
57	Identification of a human glioma antigen, SOX6, recognized by patients' sera. Oncogene, 2004, 23, 1420-1427.	2.6	71
58	T cells that are autoreactive to Î²2-glycoprotein I in patients with antiphospholipid syndrome and healthy individuals. Arthritis and Rheumatism, 2000, 43, 65-75.	6.7	70
59	Increase of oligodendrocyte progenitor cells after spinal cord injury. Journal of Neuroscience Research, 2001, 65, 500-507.	1.3	70
60	Autocrine and paracrine loops between cancer cells and macrophages promote lymph node metastasis via CCR4/CCL22 in head and neck squamous cell carcinoma. International Journal of Cancer, 2013, 132, 2755-2766.	2.3	70
61	Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Research, 2003, 13, 521-530.	0.6	69
62	Novel System Evaluating In Vivo Pathogenicity of Desmoglein 3-Reactive T Cell Clones Using Murine Pemphigus Vulgaris. Journal of Immunology, 2008, 181, 1526-1535.	0.4	69
63	Functional analysis of HOXD9 in human gliomas and glioma cancer stem cells. Molecular Cancer, 2011, 10, 60.	7.9	69
64	Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer Science, 2004, 95, 784-791.	1.7	67
65	Identification of the Genes Encoding Cancer Antigens: Implications for Cancer Immunotherapy. Advances in Cancer Research, 1996, 70, 145-177.	1.9	65
66	Isolation of a New Melanoma Antigen, MART-2, Containing a Mutated Epitope Recognized by Autologous Tumor-Infiltrating T Lymphocytes. Journal of Immunology, 2001, 166, 2871-2877.	0.4	65
67	Phase I pilot study of Wilms tumor gene 1 peptideâ€pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer. Cancer Science, 2015, 106, 397-406.	1.7	65
68	Autoreactive CD8+ cytotoxic T lymphocytes to major histocompatibility complex class I chain-related gene A in patients with BehÃ§et's disease. Arthritis and Rheumatism, 2004, 50, 3658-3662.	6.7	64
69	Epithelial Mesenchymal Transition in Human Ocular Chronic Graft-Versus-Host Disease. American Journal of Pathology, 2009, 175, 2372-2381.	1.9	61
70	Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma. European Journal of Cancer, 2017, 86, 15-27.	1.3	61
71	Involvement of local reninâ€angiotensin system in immunosuppression of tumor microenvironment. Cancer Science, 2018, 109, 54-64.	1.7	60
72	T-Cell Recognition of Human Melanoma Antigens. Journal of Immunotherapy, 1993, 14, 88-93.	1.2	59

#	Article	IF	Citations
73	Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi. International Journal of Cancer, 2006, 118, 472-476.	2.3	58
74	Prognostic Significance of Interleukin-8 and CD163-Positive Cell-Infiltration in Tumor Tissues in Patients with Oral Squamous Cell Carcinoma. PLoS ONE, 2014, 9, e110378.	1.1	57
75	Evaluation of platelet kinetics in patients with liver cirrhosis: Similarity to idiopathic thrombocytopenic purpura. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 112-118.	1.4	56
76	Isolation of cancer stem-like cells from a side population of a human glioblastoma cell line, SK-MG-1. Cancer Letters, 2010, 291, 150-157.	3.2	55
77	Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells. Gastric Cancer, 2013, 16, 100-110.	2.7	54
78	MIF Maintains the Tumorigenic Capacity of Brain Tumorâ€“Initiating Cells by Directly Inhibiting p53. Cancer Research, 2016, 76, 2813-2823.	0.4	54
79	T-cell recognition of self peptides as tumor rejection antigens. Immunologic Research, 1996, 15, 179-190.	1.3	53
80	Differential Expression of MART-1 in Primary and Metastatic Melanoma Lesions. Journal of Immunotherapy, 1997, 20, 460-465.	1.2	53
81	Aberrant Myosin 1b Expression Promotes Cell Migration and Lymph Node Metastasis of HNSCC. Molecular Cancer Research, 2015, 13, 721-731.	1.5	53
82	Single nucleotide polymorphisms of the inflammatory cytokine genes in adults with chronic immune thrombocytopenic purpura. British Journal of Haematology, 2004, 124, 796-801.	1.2	51
83	A New Melanoma Antigen Fatty Acidâ€“Binding Protein 7, Involved in Proliferation and Invasion, Is a Potential Target for Immunotherapy and Molecular Target Therapy. Cancer Research, 2006, 66, 4443-4449.	0.4	51
84	Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation. International Immunology, 2016, 28, 393-399.	1.8	50
85	Generation of Human Immunosuppressive Myeloid Cell Populations in Human Interleukin-6 Transgenic NOG Mice. Frontiers in Immunology, 2018, 9, 152.	2.2	50
86	Angiotensin II Type 1 Receptor Antagonist Attenuates Lacrimal Gland, Lung, and Liver Fibrosis in a Murine Model of Chronic Graft-Versus-Host Disease. PLoS ONE, 2013, 8, e64724.	1.1	50
87	Donor Fibroblast Chimerism in the Pathogenic Fibrotic Lesion of Human Chronic Graft-Versus-Host Disease. , 2005, 46, 4519.		49
88	Cardiomyogenic Potential of Mesenchymal Progenitors Derived from Human Circulating CD14+ Monocytes. Stem Cells and Development, 2005, 14, 676-686.	1.1	49
89	Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients. International Journal of Cancer, 2007, 120, 1704-1711.	2.3	48
90	In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer. Cancer Gene Therapy, 2002, 9, 142-148.	2.2	47

#	Article	IF	Citations
91	Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses. Cellular and Molecular Immunology, 2018, 15, 953-962.	4.8	47
92	Genomic alterations in primary cutaneous melanomas detected by metaphase comparative genomic hybridization with laser capture or manual microdissection: 6p gains may predict poor outcome. Cancer Genetics and Cytogenetics, 2005, 157, 1-11.	1.0	46
93	AMP kinase-related kinase NUAK2 affects tumor growth, migration, and clinical outcome of human melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6597-6602.	3.3	46
94	Neurogenic potential of progenitors derived from human circulating CD14 + monocytes. Immunology and Cell Biology, 2006, 84, 209-217.	1.0	45
95	T Cell Immune Responses Against Melanoma and Melanocytes in Cancer and Autoimmunity. Pigment Cell & Melanoma Research, 2000, 13, 163-169.	4.0	44
96	Identification of an immunodominant epitope on RNA polymerase III recognized by systemic sclerosis sera: Application to enzyme-linked immunosorbent assay. Arthritis and Rheumatism, 2002, 46, 2742-2747.	6.7	44
97	Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV. Cancer Gene Therapy, 2002, 9, 356-364.	2.2	44
98	Suppression of autoreactive T-cell response to glycoprotein IIb/IIIa by blockade of CD40/CD154 interaction: implications for treatment of immune thrombocytopenic purpura. Blood, 2003, 101, 621-623.	0.6	44
99	Functional recovery after spinal cord injury in mice through activation of microglia and dendritic cells after ILâ€12 administration. Journal of Neuroscience Research, 2008, 86, 1972-1980.	1.3	44
100	Induction of Immunoregulatory CD271+ Cells by Metastatic Tumor Cells That Express Human Endogenous Retrovirus H. Cancer Research, 2014, 74, 1361-1370.	0.4	44
101	Preferentially Expressed Antigen of Melanoma (PRAME) in the Development of Diagnostic and Therapeutic Methods for Hematological Malignancies. Leukemia and Lymphoma, 2003, 44, 439-444.	0.6	43
102	Effects of a Helicobacter pylori eradication regimen on anti-platelet autoantibody response in infected and uninfected patients with idiopathic thrombocytopenic purpura. Haematologica, 2006, 91, 1436-7.	1.7	43
103	Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope. British Journal of Haematology, 2005, 131, 472-479.	1.2	41
104	GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab. ELife, 2020, 9, .	2.8	41
105	Frequent Immune Responses to a Cancer/Testis Antigen, CAGE, in Patients with Microsatellite instabilityâ€"Positive Endometrial Cancer. Clinical Cancer Research, 2005, 11, 3949-3957.	3.2	40
106	Identification of HLAâ€A2â€•and A24â€restricted Tâ€cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy. International Journal of Cancer, 2010, 126, 919-929.	2.3	39
107	Activation of dendritic-like cells and neural stem/progenitor cells in injured spinal cord by GM-CSF. Neuroscience Research, 2009, 64, 96-103.	1.0	39
108	Transplantation of side population cells restores the function of damaged exocrine glands through clusterin. Stem Cells, 2012, 30, 1925-1937.	1.4	39

#	Article	IF	Citations
109	Immune-resistant mechanisms in cancer immunotherapy. International Journal of Clinical Oncology, 2020, 25, 810-817.	1.0	39
110	Enhanced antiâ€tumor effects of the PDâ€1 blockade combined with a highly absorptive form of curcumin targeting STAT3. Cancer Science, 2020, 111, 4326-4335.	1.7	39
111	A simple and reliable behavioral analysis of locomotor function after spinal cord injury in mice. Journal of Neurosurgery: Spine, 2002, 97, 142-147.	0.9	38
112	A Novel Cancer Testis Antigen That Is Frequently Expressed in Pancreatic, Lung, and Endometrial Cancers. Clinical Cancer Research, 2006, 12, 191-197.	3.2	38
113	Role of Heat Shock Protein 47, a Collagen-Binding Chaperone, in Lacrimal Gland Pathology in Patients with cGVHD. , 2007, 48, 1079.		36
114	T Helper Type 2-Biased Natural Killer Cell Phenotype in Patients with Pemphigus Vulgaris. Journal of Investigative Dermatology, 2007, 127, 324-330.	0.3	36
115	Human Melanoma Antigens Recognized by T Lymphocytes.. Keio Journal of Medicine, 1996, 45, 100-108.	0.5	35
116	Expression of a transcriptional factor, SOX6, in human gliomas. Brain Tumor Pathology, 2004, 21, 35-38.	1.1	35
117	TGF-Î²1 in Tumor Microenvironments Induces Immunosuppression in the Tumors and Sentinel Lymph Nodes and Promotes Tumor Progression. Journal of Immunotherapy, 2014, 37, 63-72.	1.2	35
118	Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. Annals of Gastroenterological Surgery, 2018, 2, 289-303.	1.2	35
119	Autoantibodies to the Amino-Terminal Fragment of Î²-Fodrin Expressed in Glandular Epithelial Cells in Patients with Sjoˆgrenâ€™s Syndrome. Journal of Immunology, 2001, 167, 5449-5456.	0.4	34
120	Systematic Identification of Human Melanoma Antigens Using Serial Analysis of Gene Expression (SAGE). Journal of Immunotherapy, 2005, 28, 10-19.	1.2	34
121	Restricted T-cell receptor Î²-chain usage by T cells autoreactive to Î²2â€“glycoprotein I in patients with antiphospholipid syndrome. Blood, 2002, 99, 2499-2504.	0.6	33
122	Targeted inhibition of ILâ€10â€secreting CD25^{âˆ’} Treg via p38 MAPK suppression in cancer immunotherapy. European Journal of Immunology, 2010, 40, 1011-1021.	1.6	33
123	Fibroblast Growth Factor-2 Is an Important Factor that Maintains Cellular Immaturity and Contributes to Aggressiveness of Osteosarcoma. Molecular Cancer Research, 2012, 10, 454-468.	1.5	32
124	T-Cell Receptor Repertoire in Tumor-Infiltrating Lymphocytes. Analysis of Melanoma-Specific Long-Term Lines. Journal of Immunotherapy, 1994, 16, 85-94.	1.2	31
125	Impairment of Plasmacytoid Dendritic Cells for IFN Production by the Ligand for Immunoglobulin-Like Transcript 7 Expressed on Human Cancer Cells. Clinical Cancer Research, 2009, 15, 5733-5743.	3.2	31
126	Simultaneous suppression of MITF and BRAF^{V600E} enhanced inhibition of melanoma cell proliferation. Cancer Science, 2009, 100, 1863-1869.	1.7	31

#	Article	IF	Citations
127	Lentiviral vector-mediated RNAi and its use for cancer research. Future Oncology, 2007, 3, 655-664.	1.1	30
128	Aberrant Fatty Acid-Binding Protein-7 Gene Expression in Cutaneous Malignant Melanoma. Journal of Investigative Dermatology, 2010, 130, 221-229.	0.3	30
129	Cancerâ€testis antigen <scp>BORIS</scp> is a novel prognostic marker for patients with esophageal cancer. Cancer Science, 2012, 103, 1617-1624.	1.7	30
130	A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2. Nature Communications, 2019, 10, 5758.	5.8	29
131	Prevention and reversal of delta-9-tetrahydrocannabinol induced depression of natural killer cell activity by interleukin-2. International Journal of Immunopharmacology, 1989, 11, 63-69.	1.1	28
132	Identification of an epigenetically silenced gene, RFX1, in human glioma cells using restriction landmark genomic scanning. Oncogene, 2004, 23, 7772-7779.	2.6	28
133	Immune responses to DNA mismatch repair enzymes hMSH2 and hPMS1 in patients with pancreatic cancer, dermatomyositis and polymyositis. International Journal of Cancer, 2005, 116, 925-933.	2.3	28
134	Involvement of Hyaluronan and Its Receptor CD44 with Choroidal Neovascularization. , 2009, 50, 4410.		28
135	CHD7 promotes proliferation of neural stem cells mediated by MIF. Molecular Brain, 2016, 9, 96.	1.3	28
136	"Smart Eye Camera": An innovative technique to evaluate tear film breakup time in a murine dry eye disease model. PLoS ONE, 2019, 14, e0215130.	1.1	28
137	Suppression by delta-9-tetrahydrocannabinol of interleukin 2-induced lymphocyte proliferation and lymphokine-activated killer cell activity. International Journal of Immunopharmacology, 1988, 10, 485-488.	1.1	26
138	Accumulation of Secretory Vesicles in the Lacrimal Gland Epithelia Is Related to Non-SjÃ¶gren's Type Dry Eye in Visual Display Terminal Users. PLoS ONE, 2012, 7, e43688.	1.1	26
139	Senescenceâ€associated secretory phenotype promotes chronic ocular graftâ€vsâ€host disease in mice and humans. FASEB Journal, 2020, 34, 10778-10800.	0.2	26
140	MHC-compatible bone marrow stromal/stem cells trigger fibrosis by activating host T cells in a scleroderma mouse model. ELife, 2016, 5, e09394.	2.8	26
141	Identification of a glioma antigen, GARC-1, using cytotoxic T lymphocytes induced by HSV cancer vaccine. International Journal of Cancer, 2006, 118, 942-949.	2.3	25
142	Novel Treatment of Chronic Graft-Versus-Host Disease in Mice Using the ER Stress Reducer 4-Phenylbutyric Acid. Scientific Reports, 2017, 7, 41939.	1.6	25
143	Suppression by Cannabinoids of a Cloned Cell Line with Natural Killer Cell Activity. Experimental Biology and Medicine, 1988, 187, 355-359.	1.1	24
144	Recognition of Shared Melanoma Antigens by Human Tumor-Infiltrating Lymphocytes. Journal of Immunotherapy, 1992, 12, 203-206.	1.2	24

#	Article	IF	Citations
145	Novel melanoma antigen, FCRL/FREB, identified by cDNA profile comparison using DNA chip are immunogenic in multiple melanoma patients. International Journal of Cancer, 2005, 114, 283-290.	2.3	24
146	Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2017, 36, 36.	3.5	24
147	Clinical significance of serum p53 antibodies in patients with ulcerative colitis and its carcinogenesis. Inflammatory Bowel Diseases, 2007, 13, 865-873.	0.9	23
148	Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402. Journal of Translational Medicine, 2010, 8, 84.	1.8	23
149	Expression and localization of aging markers in lacrimal gland of chronic graft-versus-host disease. Scientific Reports, 2013, 3, 2455.	1.6	23
150	Tumor-infiltrating lymphocytes predict survival outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy. Gynecologic Oncology, 2020, 159, 329-334.	0.6	23
151	Mechanisms of immunologic antitumor therapy: lessons from the laboratory and clinical applications. Human Immunology, 1990, 28, 198-207.	1.2	22
152	Improvement of Cancer Immunotherapy by Combining Molecular Targeted Therapy. Frontiers in Oncology, 2013, 3, 136.	1.3	22
153	miR-196b, miR-378a and miR-486 are predictive biomarkers for the efficacy of vaccine treatment in colorectal cancer. Oncology Letters, 2017, 14, 1355-1362.	0.8	22
154	Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies. Japanese Journal of Clinical Immunology, 2017, 40, 68-77.	0.0	22
155	A Pilot Study of Human Interferon Â Gene Therapy for Patients with Advanced Melanoma by in vivo Transduction Using Cationic Liposomes. Japanese Journal of Clinical Oncology, 2008, 38, 849-856.	0.6	21
156	Sox6 Up-Regulation by Macrophage Migration Inhibitory Factor Promotes Survival and Maintenance of Mouse Neural Stem/Progenitor Cells. PLoS ONE, 2013, 8, e74315.	1.1	21
157	Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma. Melanoma Research, 2017, 27, 326-334.	0.6	21
158	Generation of Human Melanocytes from Induced Pluripotent Stem Cells. Methods in Molecular Biology, 2013, 989, 193-215.	0.4	20
159	Cascade of Inflammatory, Fibrotic Processes, and Stress-Induced Senescence in Chronic GVHD-Related Dry Eye Disease. International Journal of Molecular Sciences, 2021, 22, 6114.	1.8	20
160	Suppression of Alkali Burn-Induced Corneal Neovascularization by Dendritic Cell Vaccination Targeting VEGF Receptor 2. , 2008, 49, 2172.		19
161	Presence and Physiologic Function of the Reninâ€“Angiotensin System in Mouse Lacrimal Gland. , 2012, 53, 5416.		19
162	NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation. Cancer Research, 2015, 75, 2708-2715.	0.4	19

#	Article	IF	Citations
163	Induction of protective and therapeutic antitumor immunity by a DNA vaccine with a glioma antigen, SOX6. International Journal of Cancer, 2008, 122, 2274-2279.	2.3	18
164	Cancerâ€induced immunosuppressive cascades and their reversal by molecularâ€targeted therapy. Annals of the New York Academy of Sciences, 2013, 1284, 80-86.	1.8	18
165	Immunochemoradiotherapy for Patients with Oral Squamous Cell Carcinoma: Augmentation of OK-432-Induced Helper T Cell 1 Response by 5-FU and X-ray Irradiation. Neoplasia, 2013, 15, 805-814.	2.3	18
166	Synergistic antiproliferative effect of imatinib and adriamycin in plateletâ€derived growth factor receptorâ€expressing osteosarcoma cells. Cancer Science, 2015, 106, 875-882.	1.7	18
167	New Cancer Therapy by Immunomanipulation. Cornea, 2000, 19, S2-S6.	0.9	18
168	Rapid and efficient generation of lentivirally gene-modified dendritic cells from DC progenitors with bone marrow stromal cells. Journal of Immunological Methods, 2002, 271, 153-165.	0.6	17
169	Identification of a WT1 proteinâ€derived peptide, WT1₁₈₇, as a HLAâ€A*0206â€restricted, WT1â€specific CTL epitope. Microbiology and Immunology, 2008, 52, 551-558.	0.7	17
170	Guidelines for clinical evaluation of antiâ€cancer drugs. Cancer Science, 2021, 112, 2563-2577.	1.7	17
171	Prognostic Impact of Expression of Bcl-2 and Bax Genes in Circulating Immune Cells Derived from Patients with Head and Neck Carcinoma. Neoplasia, 2013, 15, 305-IN35.	2.3	16
172	NOD-<i>Rag2^{null} IL-2RÎ³^{null}</i> Mice: An Alternative to NOG Mice for Generation of Humanized Mice. Experimental Animals, 2014, 63, 321-330.	0.7	16
173	Identification of bladder cancer antigens recognized by IgG antibodies of a patient with metastatic bladder cancer. International Journal of Cancer, 2004, 108, 712-724.	2.3	15
174	Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Antiâ€“PD-1 Therapy. Journal of Investigative Dermatology, 2019, 139, 1490-1496.	0.3	15
175	Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series. BMC Cancer, 2020, 20, 196.	1.1	15
176	Dendritic cell based personalized immunotherapy based on cancer antigen research. Frontiers in Bioscience - Landmark, 2008, 13, 1952.	3.0	15
177	Expansion of Tumor-Infiltrating Lymphocytes from Human Tumors Using the T-Cell Growth Factors Interleukin-2 and Interleukin-4. Journal of Immunotherapy, 1993, 14, 336-347.	1.2	14
178	Clinical significance of MART-1 and HLA-A2 expression and CD8+ T cell infiltration in melanocytic lesions in HLA-A2 phenotype patients. Journal of Dermatological Science, 2001, 25, 36-44.	1.0	14
179	A Novel Protein Highly Expressed in Testis Is Overexpressed in Systemic Sclerosis Fibroblasts and Targeted by Autoantibodies. Journal of Immunology, 2003, 171, 6883-6890.	0.4	14
180	Immunohistochemical analysis of SOX6 expression in human brain tumors. Brain Tumor Pathology, 2004, 21, 117-120.	1.1	14

#	Article	IF	Citations
181	Augmentation of Antitumor Immune Responses by Multiple Intratumoral Inoculations of Replication-Conditional HSV and Interleukin-12. Journal of Immunotherapy, 2004, 27, 92-98.	1.2	14
182	Suppression of Choroidal Neovascularization by Dendritic Cell Vaccination Targeting VEGFR2. , 2007, 48, 4795.		14
183	Development of Immunotherapy for Pancreatic Cancer. Pancreas, 2004, 28, 320-325.	0.5	13
184	Possible involvement of allogeneic antigens recognised by donor-derived CD4+ cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy. British Journal of Haematology, 2006, 132, 56-65.	1.2	13
185	Isolation and characterization of dendritic cells from common marmosets for preclinical cell therapy studies. Immunology, 2008, 123, 566-574.	2.0	13
186	Functional Role of Lacrimal Gland Fibroblasts in a Mouse Model of Chronic Graft-Versus-Host Disease. Cornea, 2018, 37, 102-108.	0.9	13
187	Programmed cell death ligand 1 (PD-L1) blockade attenuates metastatic colon cancer growth in cAMP-response element-binding protein (CREB)-binding protein (CBP)/Î²-catenin inhibitor-treated livers. Oncotarget, 2019, 10, 3013-3026.	0.8	13
188	Identification of a Novel Cancer-Testis Antigen CRT2 Frequently Expressed in Various Cancers Using Representational Differential Analysis. Clinical Cancer Research, 2007, 13, 6267-6274.	3.2	12
189	Dendritic Cells Transduced with Autoantigen FCRLA Induce Cytotoxic Lymphocytes and Vaccinate against Murine B-Cell Lymphoma. Journal of Investigative Dermatology, 2007, 127, 2818-2822.	0.3	12
190	Inter-patient and Intra-tumor Heterogeneity in the Sensitivity to Tumor-targeted Immunity in Colorectal Cancer. Japanese Journal of Clinical Immunology, 2017, 40, 54-59.	0.0	12
191	Identification of a neuron-specific human gene, KIAA1110, that is a guanine nucleotide exchange factor for ARF1. Biochemical and Biophysical Research Communications, 2007, 364, 737-742.	1.0	11
192	Autoreactive T-cell responses to myeloperoxidase in patients with antineutrophil cytoplasmic antibody-associated vasculitis and in healthy individuals. Modern Rheumatology, 2008, 18, 593-600.	0.9	11
193	Growth inhibition and apoptosis by an active component of OK-432, a streptococcal agent, via Toll-like receptor 4 in human head and neck cancer cell lines. Oral Oncology, 2012, 48, 678-685.	0.8	11
194	Ocular Surface and Tear Film Characteristics in a Sclerodermatous Chronic Graft-Versus-Host Disease Mouse Model. Cornea, 2018, 37, 486-494.	0.9	11
195	Therapeutic potential of tranilast for the treatment of chronic graft-versus-host disease in mice. PLoS ONE, 2018, 13, e0203742.	1.1	11
196	Transcription factor homeobox D9 is involved in the malignant phenotype of cervical cancer through direct binding to the human papillomavirus oncogene promoter. Gynecologic Oncology, 2019, 155, 340-348.	0.6	11
197	Adoptive cell therapy using tumorâ€infiltrating lymphocytes for melanoma refractory to immuneâ€checkpoint inhibitors. Cancer Science, 2021, 112, 3163-3172.	1.7	11
198	Autoreactive T-cell responses to myeloperoxidase in patients with antineutrophil cytoplasmic antibody-associated vasculitis and in healthy individuals. Modern Rheumatology, 2008, 18, 593-600.	0.9	11

#	Article	IF	Citations
199	Immunological detection of altered signaling molecules involved in melanoma development. Cancer and Metastasis Reviews, 2005, 24, 357-366.	2.7	10
200	The RNA Silencing Technology Applied by Lentiviral Vectors in Oncology. Methods in Molecular Biology, 2010, 614, 187-199.	0.4	10
201	Adjuvant effects of formalinâ€inactivated HSV through activation of dendritic cells and inactivation of myeloidâ€derived suppressor cells in cancer immunotherapy. International Journal of Cancer, 2011, 128, 119-131.	2.3	10
202	Functional analysis of a novel glioma antigen, EFTUD1. Neuro-Oncology, 2014, 16, 1618-1629.	0.6	10
203	Targeting ALCAM in the cryo-treated tumour microenvironment successfully induces systemic anti-tumour immunity. European Journal of Cancer, 2016, 62, 54-61.	1.3	10
204	Inhibition of Vascular Adhesion Proteinâ€1 for Treatment of Graftâ€Versusâ€Host Disease in Mice. FASEB Journal, 2018, 32, 4085-4095.	0.2	10
205	Siglec-7 is a predictive biomarker for the efficacy of cancer vaccination against metastatic colorectal cancer. Oncology Letters, 2020, 21, 1-1.	0.8	10
206	Pilot study of WT1 peptideâ€pulsed dendritic cell vaccination with docetaxel in esophageal cancer. Oncology Letters, 2018, 16, 1348-1356.	0.8	9
207	Positive Effects of Oral Antibiotic Administration in Murine Chronic Graft-Versus-Host Disease. International Journal of Molecular Sciences, 2021, 22, 3745.	1.8	8
208	Autoreactive T cells to the P3A+ isoform of AChR Î± subunit in myasthenia gravis. Journal of Neuroimmunology, 2003, 137, 177-186.	1.1	6
209	Reduced Expression of VAMP8 in Lacrimal Gland Affected by Chronic Graft-versus-Host Disease. Journal of Ophthalmology, 2017, 2017, 1-10.	0.6	6
210	NUAK2 localization in normal skin and its expression in a variety of skin tumors with YAP. Journal of Dermatological Science, 2020, 97, 143-151.	1.0	6
211	Identification of Novel HLA-A*24:02-Restricted Epitope Derived from a Homeobox Protein Expressed in Hematological Malignancies. PLoS ONE, 2016, 11, e0146371.	1.1	6
212	Immunotherapy Using T Cell Defined Tumor Antigens for Melanoma. Microbiology and Immunology, 1998, 42, 803-813.	0.7	5
213	Cluster of differentiation 30 expression in lacrimal gland and conjunctival tissues in patients with SjÃ¶gren's syndrome. Medicine (United States), 2019, 98, e16390.	0.4	5
214	MIF: functions in brain and glioblastoma. Oncotarget, 2017, 8, 46706-46707.	0.8	4
215	Identification of Human Tumor Antigens Recognized by T-Cells and Their Use for Immunotherapy. International Journal of Hematology, 2003, 77, 427-434.	0.7	3
216	Intratumoral Injection of BCG-CWS-Pretreated Dendritic Cells Following Tumor Cryoablation. Methods in Molecular Biology, 2014, 1139, 145-153.	0.4	3

#	Article	IF	Citations
217	TPT1 Supports Proliferation of Neural Stem/Progenitor Cells and Brain Tumor Initiating Cells Regulated by Macrophage Migration Inhibitory Factor (MIF). Neurochemical Research, 2022, 47, 2741-2756.	1.6	3
218	Development of Personalized Combination Cancer Immunotherapy Based on the Patientsâ€™ Immune Status. , 2015, , 255-266.		2
219	Roles of Signaling Pathways in Cancer Cells and Immune Cells in Generation of Immunosuppressive Tumor-Associated Microenvironments. , 2013, , 307-323.		2
220	Splenic Macrophages Maintain the Anti-Platelet Autoimmune Response Via Uptake of Opsonized Platelets in Patients with Chronic ITP.. Blood, 2005, 106, 221-221.	0.6	2
221	Novel elucidation and treatment of pancreatic chronic graft-versus-host disease in mice. Royal Society Open Science, 2018, 5, 181067.	1.1	1
222	In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer. , 0, .		1
223	Human melanoma antigens recognized by CD8+ T cells. , 2003, , 47-74.		1
224	Macrophage migration inhibitory factor (MIF) promotes cell survival and proliferation of neural stem/progenitor cells. Development (Cambridge), 2012, 139, e1908-e1908.	1.2	1
225	Inflammation and pathogenic fibrosis in human ocular chronic graft versus host disease. Inflammation and Regeneration, 2008, 28, 529-536.	1.5	1
226	Chemoimmunotherapy of Spontaneous Mammary Tumors in C3H/OuJ Mice by Cyclophosphamide and Interleukin-2. Annals of the New York Academy of Sciences, 1988, 532, 482-485.	1.8	0
227	Donor mesenchymal stem cells trigger chronic graft-versus-host disease following minor antigen-mismatched bone marrow transplantation. Nature Precedings, 2012, , .	0.1	0
228	Personalized Cancer Immunotherapy: Immune Biomarkers and Combination Immunotherapy. , 2016, , 349-358.		0
229	Immunobiology of theÂMelanoma Microenvironment. , 2018, , 133-142.		0
230	Immunotherapy of Melanoma Using T-Cell-Defined Antigens. , 2000, , 77-92.		0
231	Impaired Platelet Production and Autoantibody-Mediated Platelet Destruction Are Two Major Causes for Prolonged Thrombocytopenia after Allogeneic HSCT.. Blood, 2004, 104, 2256-2256.	0.6	0
232	Multi-Lineage Potential of Human Monocyte-Derived Mesenchymal Progenitors (MOMPs).. Blood, 2004, 104, 3595-3595.	0.6	0
233	Human Tumor Antigens Recognized by T Cells and Their Implications for Cancer Immunotherapy. , 2012, , 335-345.		0
234	Identification of human melanoma antigens recognized by T cells and their use for immuno-gene therapy.. The Journal of the Japanese Society of Lymphoreticular Tissue Research, 1997, 37, 137-144.	0.0	0

#	Article	IF	Citations
235	Cancer Induced Immunosuppression and Its Modulation by Signal Inhibitors. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 287-301.	0.1	0
236	Challenges and experiences to develop a Japanese language course for international medical students in Japan: Maximising acquisition of Japanese language by applying adult learning theories. Asia Pacific Scholar, 2022, 7, 3-8.	0.2	0
237	Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest. Cancer Immunology, Immunotherapy, 1994, 39, 73-83.	2.0	0